Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22277457 | 0.97 | MAPT (0.34) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL22277506 | 0.97 | MAPT (0.34) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406282 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406132 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406127 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406276 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405927 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405923 | 0.96 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405955 | 0.95 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406413 | 0.95 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-20160083653-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME AND LIQUID CRYSTAL DISPLAY INCLUDING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY COMPRISING THE LIQUID CRYSTAL COMPOSITION | NAP1L1, SLFN12, RCC2 | MAPT 309/4885GAA 4846/4885MEN1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.